Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database.
10.3349/ymj.2017.58.3.564
- Author:
Kyounghoon PARK
1
;
Mick SOUKAVONG
;
Jungmee KIM
;
Kyoung Eun KWON
;
Xue Mei JIN
;
Joongyub LEE
;
Bo Ram YANG
;
Byung Joo PARK
Author Information
1. Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea. bjpark@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Imipenem;
KIDS-KAERS database;
signal;
pharmacovigilance;
pharmacoepidemiology
- MeSH:
Anti-Bacterial Agents;
Canada;
Data Mining;
Drug Eruptions;
Drug Labeling;
Drug-Related Side Effects and Adverse Reactions;
France;
Germany;
Heart Arrest;
Heart Failure;
Hypokalemia;
Imipenem*;
Italy;
Japan;
Korea*;
Myocardial Infarction;
Odds Ratio;
Pharmacoepidemiology;
Pharmacovigilance;
Prostate;
Switzerland
- From:Yonsei Medical Journal
2017;58(3):564-569
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To detect signals of adverse drug events after imipenem treatment using the Korea Institute of Drug Safety & Risk Management-Korea adverse event reporting system database (KIDS-KD). MATERIALS AND METHODS: We performed data mining using KIDS-KD, which was constructed using spontaneously reported adverse event (AE) reports between December 1988 and June 2014. We detected signals calculated the proportional reporting ratio, reporting odds ratio, and information component of imipenem. We defined a signal as any AE that satisfied all three indices. The signals were compared with drug labels of nine countries. RESULTS: There were 807582 spontaneous AEs reports in the KIDS-KD. Among those, the number of antibiotics related AEs was 192510; 3382 reports were associated with imipenem. The most common imipenem-associated AE was the drug eruption; 353 times. We calculated the signal by comparing with all other antibiotics and drugs; 58 and 53 signals satisfied the three methods. We compared the drug labelling information of nine countries, including the USA, the UK, Japan, Italy, Switzerland, Germany, France, Canada, and South Korea, and discovered that the following signals were currently not included in drug labels: hypokalemia, cardiac arrest, cardiac failure, Parkinson's syndrome, myocardial infarction, and prostate enlargement. Hypokalemia was an additional signal compared with all other antibiotics, and the other signals were not different compared with all other antibiotics and all other drugs. CONCLUSION: We detected new signals that were not listed on the drug labels of nine countries. However, further pharmacoepidemiologic research is needed to evaluate the causality of these signals.
